Cancer | Jotup

Genetron Health Partners with Guizhou Province’s Dafang County to Lead Liver Cancer Early Screening Project

Medicine, Health sciences, Medical terminology, Prevention, Health, Cancer screening, Oncology, Cancer prevention, Cancer, Screening, Liver cancer, Preventive healthcare

Thursday, July 29, 2021 - 9:35am

BEIJING, July 29, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (Genetron Health or the Company, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will work with Guizhou Provinces Dafang County authorities to lead the Early Screening for Regional Liver Cancer Prevention and Containment Demonstration Project.

Key Points:

BEIJING, July 29, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (Genetron Health or the Company, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will work with Guizhou Provinces Dafang County authorities to lead the Early Screening for Regional Liver Cancer Prevention and Containment Demonstration Project.
Genetron Health will work with its partners to carry out early screening, diagnosis, treatment, follow-up screenings, and patient management for high risk liver cancer groups in Guizhous Dafang County.
Genetron Health will establish a comprehensive cancer prevention and containment model that prioritizes prevention, and integrates it with long-term screening management, diagnosis, and treatment.
In 2019, Chinas National Cancer Center used HCCscreens liver cancer early screening liquid biopsy technology in a large-scale prospective cohort study.

Basilea announces U.S. FDA Orphan Drug Designation granted to lisavanbulin for the treatment of malignant glioma

Cancer, Health, Brain tumor, Oncology, Basilea Pharmaceutica, Glioblastoma, Glioma, Orphan drug, Paclitaxel trevatide, Pelareorep

Thursday, July 29, 2021 - 6:15am

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Basileas tumor checkpoint controller, lisavanbulin, for the treatment of malignant glioma (brain cancer).

Key Points:

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Basileas tumor checkpoint controller, lisavanbulin, for the treatment of malignant glioma (brain cancer).
Dr. Marc Engelhardt, Chief Medical Officer, commented: The Orphan Drug Designation of lisavanbulin by the U.S. FDA is an important milestone for the development of lisavanbulin.
Glioblastoma is associated with a poor prognosis and there are only very limited therapeutic options available.
Lisavanbulin, as a targeted treatment, could be a useful new approach to expand the treatment options for patients with this devastating disease.

Pharmadrug Announces Positive Research Results of Cepharanthine to Treat Multiple Cancers

Cancer, Clusterin, Anti-inflammatory, Branches of biology, Virotherapy, Clusters of differentiation

Wednesday, July 28, 2021 - 1:51pm

Toronto, Ontario--(Newsfile Corp. - July 28, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce the completion of their preclinical cancer study which evaluated cepharanthine-2HCl, the active pharmaceutical ingredient in PD-001, the Company's patented oral formulation of cepharanthine. The results from the study validate cepharanthine's potential in treating different types of cancer including esophageal, colorectal, liver and skin. The results also provide confidence in the Company's plan to dedicate resources to advance PD-001 through FDA IND-enabling studies to support Phase 1 and 2 clinical studies. The study was conducted by a respected contract research organization with deep expertise in preclinical oncology model development and drug testing and data corresponding to all studied cancer cell lines have now been reported to the Company.

Key Points:

Based on the de-risked and positive results from the study, the Company has initiated the following activities:
Broadening intellectual property strategy with planned filing of provisional patents on cepharanthine for specific cancers.
Cepharanthine has been shown in preclinical efficacy models to restore cancer cell sensitivity to multiple unrelated classes of chemotherapy.
In clinical research, Cepharanthine has been shown to exhibit multiple pharmacological properties including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties5.
The Company is focused on advancing the clinical development of an improved oral formulation of Cepharanthine (PD-001) to treat rare cancers and infectious diseases.

Turning Point Therapeutics to Host Second Quarter 2021 Conference Call

Cancer, Health sciences, Health

Wednesday, July 28, 2021 - 9:15pm

SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report second quarter financial results following the close of U.S. financial markets on August 9.

Key Points:

SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report second quarter financial results following the close of U.S. financial markets on August 9.
President and CEO Athena Countouriotis, M.D., will host the call, which will include a question and answer session.
The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
These forward-looking statements are based upon Turning Point Therapeutics current expectations and involve assumptions that may never materialize or may prove to be incorrect.

Delcath Systems Schedules Conference Call to Report 2021 Second Quarter Financial Results

Medical specialties, Clinical medicine, Medicine, Hepatology, Cancer treatments, Cancer, Oncology, Delcath Systems, Percutaneous hepatic perfusion, Interventional oncology, Liver cancer, Chemotherapy

Wednesday, July 28, 2021 - 2:00pm

NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on August 10, 2021 at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2021.

Key Points:

NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on August 10, 2021 at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2021.
To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
The call will also be available over the Internet and accessible at:
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.
The companys proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

FDA Clears Promega OncoMate™ MSI Dx Analysis System

Wednesday, July 28, 2021 - 6:00pm

The OncoMate MSI Dx Analysis System (OncoMate MSI), developed by Promega , has been cleared by the US Food and Drug Administration (FDA) as an IVD medical device to determine microsatellite instability (MSI) status in colorectal cancer tumors.

Key Points:

The OncoMate MSI Dx Analysis System (OncoMate MSI), developed by Promega , has been cleared by the US Food and Drug Administration (FDA) as an IVD medical device to determine microsatellite instability (MSI) status in colorectal cancer tumors.
View the full release here: https://www.businesswire.com/news/home/20210728005823/en/
The OncoMate MSI Dx Analysis System developed by Promega has been cleared by the US Food and Drug Administration (FDA) as an in vitro diagnostic medical device to determine microsatellite instability (MSI) status in colorectal cancer tumors.
Promega also intends to seek regulatory clearance for a Promega MSI IVD in China where the Promega MSI technology received innovation status and priority review by the National Medical Products Administration (NMPA).
To learn more about the OncoMate MSI Dx Analysis System, visit: www.promega.com/OncoMateIVD
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry.

PerkinElmer Expands KRAS Oncology Drug Discovery Assays with New Ready-to-Use AlphaLISA Kits

Research, Medical devices, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Natural sciences, KRAS, Branches of biology, Chemistry, Laboratory techniques, Pancreatic cancer, SOS1, Assay, Ras GTPase, Cancer

Wednesday, July 28, 2021 - 1:00pm

Researchers will now be able to choose between PerkinElmers HTRF or AlphaLISA assays to use the best methods for their individual labs.

Key Points:

Researchers will now be able to choose between PerkinElmers HTRF or AlphaLISA assays to use the best methods for their individual labs.
The Companys AlphaLISA and HTRF kits are the first ready-to-use homogenous assays for KRAS/SOS1 inhibition analysis on the market.
PerkinElmers AlphaLISA and HTRF kits streamline workflows by offering fully validated kits to identify novel KRAS inhibitors in a no-wash format with no optimization necessary, and each kit comes with recombinant proteins, detection reagents, and assay buffers.
Because KRAS mutations are found in numerous types of cancer, from lung to colorectal to pancreatic cancers, its a prime drug target.

New European Published Study Shows LuViva Detects 20% More Precancerous and Cancerous Cervical Disease than HPV Test

Biotechnology, Other Health, Health, General Health, Women, Oncology, Other Science, Medical devices, Research, Consumer, Science, Cancer, Infectious causes of cancer, Human papillomavirus infection, Positive and negative predictive values, Cervical screening, HPV-positive oropharyngeal cancer

Wednesday, July 28, 2021 - 2:00pm

In addition, the confidence that a negative LuViva result truly indicated no significant disease (negative predictive value) was 90% for LuViva and 81% for HPV.

Key Points:

In addition, the confidence that a negative LuViva result truly indicated no significant disease (negative predictive value) was 90% for LuViva and 81% for HPV.
The confidence that a positive test result truly indicated presence of disease (positive predictive value) was about the same for both LuViva (35%) and HPV (37%).
According to new U.S. guidelines, women with this high a likelihood of cervical disease or higher need to either have tissue removed for a definitive diagnosis or consider immediate treatment.
The Companys first product is the LuViva Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care.

Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-1966, an Investigational Radiopharmaceutical for the Treatment of Head and Neck and Bladder Cancers Expressing FGFR3

Tyrosine kinase receptors, Clusters of differentiation, Infectious causes of cancer, Fibroblast growth factor receptor 3, Bladder cancer, Branches of biology, Cancer, Radiation therapy, Physical sciences, Radiation, Fibroblast growth factor receptor, Natural sciences

Wednesday, July 28, 2021 - 9:15pm

We have an opportunity to selectively deliver alpha particles to these tumors and use precision radiation therapy as a new treatment paradigm.

Key Points:

We have an opportunity to selectively deliver alpha particles to these tumors and use precision radiation therapy as a new treatment paradigm.
While the currently approved pan-FGFR inhibitor for bladder cancer requires the presence of a specific mutation, our approach requires only over-expression of FGFR3.
The information that Fusion posts on this website could be deemed to be material information.
As a result, Fusion encourages investors, media and others interested to review the information that Fusion posts there on a regular basis.

Bridge Medicines Enters Exclusive License Agreement with Cornell University for UBR5 Inhibitor Program to Treat Resistant Cancers

Clinical medicine, Cancer immunotherapy, Medicine, UBR5, Clusters of differentiation, Immunotherapy, PD-L1, Breast cancer, Cancer

Wednesday, July 28, 2021 - 1:08pm

Consequently, attacking the UBR5 target may work well in combination with other immune regulators, such as those that target the PD-L1 pathway.

Key Points:

Consequently, attacking the UBR5 target may work well in combination with other immune regulators, such as those that target the PD-L1 pathway.
Collectively, these data support targeting UBR5 as a novel immunotherapy to treat highly aggressive breast cancers that resist conventional therapies.
"We are very excited to bring the UBR5 program into Bridge Medicines," said Bill Polvino, CEO of Bridge Medicines.
Bridge Medicines is a pioneering drug-discovery company focused on advancing promising early technologies in major academic institutions from proof-of-concept to clinical development.